Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Clinical-stage biopharma resTORbio, Inc. (NASDAQ:TORC) went public Jan. 26, offering 5.67 million shares at $15 each.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Bank of America Merrill Lynch analyst Tazeen Ahmad initiated coverage of Restorbio shares with a Buy rating and $23 price target.
The Thesis
Restorbio's lead asset RTB101, which targets the mTOR pathway, is in a Phase 2b clinical trial to reduce respiratory tract infections in the elderly, Ahmad said in a Tuesday note. Restorbio is an attractive investment opportunity for the following reasons, the analyst said:
- Its pipeline, which addresses significant unmet needs to improve weakened immune systems among the elderly.
- Prior Phase 2a data showing favorable efficacy and safety data for RTB101 in treating respiratory tract infections.
- Its potential for expanding the label to include central nervous system and cardiovascular diseases.
- A novel mechanism and the most advanced immunosenescence-targeted clinical program.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
BofA estimates risk-adjusted peak sales of $447 million for RTB101 in 2031. The Phase 2b readout in the second half of 2018 and the potential to expand RTB101's opportunities could drive significant upside to BofA's estimates, Ahmad said.
In a blue-sky scenario, BofA expects Restorbio shares to be valued at $66.
The Price Action
Restorbio shares were up 3.94 percent at $19.50 at the close Tuesday.
Related Links:
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Attention Biotech Investors: February PDUFA Catalysts Come Calling
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.